ClinicalTrials.gg
CompletedNCT03446976Updated Jul 26, 2019

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

A Phase 1 interventional study of CT-P13 SC Auto-injector and CT-P13 SC Pre-filled Syringe in Health, Subjective, sponsored by Celltrion. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-26.

Sponsored by Celltrion · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study compares two administration methods of CT-P13. Half of participants will receive CT-P13 by pre-filled syringe while the other half will receive CT-P13 by auto-injector.

Read the detailed description

This is a Phase I Study to Compare Pharmacokinetics and Safety between CT-P13 SC Pre-filled Syringe and CT-P13 SC Auto-injector in Healthy Subjects. A total of 218 healthy subjects will be enrolled.

02

Conditions studied

  • Health, Subjective
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subject
  • Subject voluntarily agrees to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Subject with medical history and/or condition
  • Female who is pregnant or breastfeeding, or .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    CT-P13 SC Auto-injector

    CT-P13 SC Auto-injector

    Biological: CT-P13 SC Auto-injector

  • Experimental
    CT-P13 SC Pre-filled Syringe

    CT-P13 SC Pre-filled Syringe

    Biological: CT-P13 SC Pre-filled Syringe

Interventions

  • BiologicalCT-P13 SC Auto-injector

    Each subject may receive single dose by subcutaneous administration using Auto-Injector

  • BiologicalCT-P13 SC Pre-filled Syringe

    Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe

06

What researchers measure

Primary outcomes

  1. To demonstrate comparable pharmacokinetics (PK) of CT-P13 subcutaneous (SC) administered by auto-injector (AI) versus pre-filled syringe (PFS) in healhty subjects.

    Pharmacokinetics will be assessed by AUC

    Time frame: over 12 weeks

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2018
First posted
Feb 27, 2018
StartActual
Feb 21, 2018
Primary completionActual
Jul 26, 2018
CompletionActual
Jul 26, 2018
Last update
Jul 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03446976
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Feb 21, 2018
Primary completion
Jul 26, 2018
Completion
Jul 26, 2018
Last update
Jul 26, 2019

Study contacts

SuEun Song
study chair · Celltrion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion